Jiangsu Vanguard Pharmaceutical Co., Ltd.

Primary Objective: This study used sulindac tablets (200 mg) developed by Jiangsu Wango Pharmaceutical Co., Ltd. as the test formulation, and sulindac tablets (200 mg, trade name: Sulindac®) manufactured by Watson Pharma Private Ltd. as the reference formulation, in accordance with relevant regulations for bioequivalence studies, to evaluate the bioequivalence of the test and reference formulations under fasting/postprandial conditions. Secondary Objective: To observe the safety of the test and reference formulations, sulindac tablets (Sulindac®), in healthy participants.

Primary Study Objective: To evaluate the pharmacokinetic characteristics and bioequivalence of a single oral dose of atorvastatin calcium tablets (20 mg, sponsor: Jiangsu Wango Pharmaceutical Co., Ltd.) and the reference formulation (Lipitor®, 20 mg, licensee: Pfizer Inc.) after a meal in healthy adult participants in China. Secondary Study Objective: To evaluate the safety of atorvastatin calcium tablets (20 mg, test formulation: 20 mg) and the reference formulation (Lipitor®, 20 mg) in healthy adult participants in China.

Primary Study Objective: To evaluate the pharmacokinetic characteristics and bioequivalence of a single oral dose of tadalafil tablets (test formulation, strength: 20 mg, sponsor: Jiangsu Wango Pharmaceutical Co., Ltd.) and reference formulation (trade name: Cialis®, strength: 20 mg, licensee: A. Menarini GmbH) after a meal in healthy adult male subjects in China. Secondary Study Objective: To investigate the safety of tadalafil tablets (test formulation, strength: 20 mg) and reference formulation (trade name: Cialis®, strength: 20 mg) in healthy adult male subjects in China.